In vitro methods for screening libraries of antibody fragments (generally scFv or Fab) expressed as fusion proteins on the surface of bacteriophage or yeast cells are well-established. These strategies are noted for their high-throughput which increases the probability of finding antibodies that bind to the targets of interest. However, they are limited by the fact that selected antibodies do not undergo mammalian cell post-translational quality control, and thus do not have predictable expression or optimal biophysical properties in mammalian cell production systems.
Vaccinex has identified a need for a high-throughput, mammalian-based selection platform and has met this challenge by combining proprietary, large-scale library construction techniques with a novel vaccinia virus display method into one platform called ActivMAb®. ActivMAb® combines the throughput of phage and yeast display with mammalian-cell quality control in one successful platform to enable selection of full-length human IgG with built-in manufacturability and favorable biophysical properties ideally suited for downstream development.
Vaccinex offers full service selection, characterization and functional assessment for our drug-development partners and clients. Contact us to learn how we can help you succeed with your selection projects.